Anteris Technologies Global Corp. (NASDAQ:AVR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Anteris Technologies Global Corp. (NASDAQ:AVR) have been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $16.00.

A number of equities research analysts have recently commented on AVR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research note on Friday, August 14th.

Anteris Technologies Global Stock Up 0.4%

AVR opened at $8.37 on Thursday. The firm has a market cap of $815.74 million, a P/E ratio of -4.29 and a beta of 1.80. Anteris Technologies Global has a 52 week low of $3.30 and a 52 week high of $11.06. The business’s fifty day simple moving average is $8.70 and its 200 day simple moving average is $7.87.

Anteris Technologies Global (NASDAQ:AVR) last announced its earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The firm had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same period in the previous year, the firm posted ($0.58) EPS. As a group, equities analysts expect that Anteris Technologies Global will post -1.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd sold 558,633 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $8.20, for a total transaction of $4,580,790.60. Following the transaction, the insider owned 6,633,314 shares of the company’s stock, valued at $54,393,174.80. This represents a 7.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders sold 3,008,459 shares of company stock valued at $25,243,576. Insiders own 4.50% of the company’s stock.

Institutional Investors Weigh In On Anteris Technologies Global

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc acquired a new position in Anteris Technologies Global in the second quarter valued at $78,000. Abel Hall LLC acquired a new stake in Anteris Technologies Global in the 1st quarter worth about $63,000. Bartlett & CO. Wealth Management LLC grew its holdings in Anteris Technologies Global by 174.5% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock valued at $79,000 after buying an additional 8,200 shares during the period. One68 Global Capital LLC purchased a new stake in Anteris Technologies Global in the 2nd quarter valued at about $128,000. Finally, J. Derek Lewis & Associates Inc. acquired a new position in shares of Anteris Technologies Global during the 4th quarter valued at about $70,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. is a medical device company focused on developing advanced technologies for structural heart disease. Its primary product candidate is the DurAVR transcatheter heart valve, designed to treat aortic valve stenosis through a minimally invasive transcatheter aortic valve replacement procedure.

The DurAVR valve is based on Anteris’ ADAPT tissue-engineering technology and is manufactured as a single-piece valve intended to replicate the performance and natural hemodynamics of a healthy human aortic valve.